Basis: Current FMP quote-based enterprise value / four-quarter operating cash flow less absolute capital expenditures. Source: stored company filings and market data; unavailable inputs remain N/A.
The EV/FCF ratio is N/A as of 2026-10-06T21:22:59.793Z.
Calculation as of: 2026-10-06T21:22:59.793Z.
Quote observation: 2026-10-06T20:00:00.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 23d17170dcd90d56222e16e6e1c46ca5d6e49f0f5e08d353dc7d5f06f7b1586d
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
EV/FCF RATIO
N/A
Market Cap
$9.63B
EV/FCF Ratio
35.75x
TTM Avg
39.30x
3Y Avg
42.86x
5Y Avg
42.86x
Market Cap
$9.66B
EV/FCF Ratio
24.71x
TTM Avg
28.62x
3Y Avg
26.92x
5Y Avg
24.53x
Market Cap
$9.87B
EV/FCF Ratio
89.84x
TTM Avg
79.84x
3Y Avg
80.84x
5Y Avg
178.26x
Market Cap
$9.93B
EV/FCF Ratio
30.06x
TTM Avg
26.26x
3Y Avg
37.03x
5Y Avg
50.43x
Market Cap
$10.03B
EV/FCF Ratio
28.67x
TTM Avg
36.84x
3Y Avg
40.02x
5Y Avg
35.83x
Market Cap
$9.21B
EV/FCF Ratio
116.51x
TTM Avg
164.71x
3Y Avg
91.71x
5Y Avg
80.37x
Market Cap
$10.13B
EV/FCF Ratio
N/A
TTM Avg
31.78x
3Y Avg
40.89x
5Y Avg
51.25x
| NAME | MARKET CAP | EV/FCF RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Vaxcyte, Inc. (PCVX) | $9.63B | N/A | N/A | N/A | N/A |
| Krystal Biotech, Inc. (KRYS)vs › | $9.63B | 35.75x | 39.30x | 42.86x | 42.86x |
| Henry Schein, Inc. (HSIC)vs › | $9.66B | 24.71x | 28.62x | 26.92x | 24.53x |
| Repligen Corporation (RGEN)vs › | $9.87B | 89.84x | 79.84x | 80.84x | 178.26x |
| Bio-Rad Laboratories, Inc. (BIO)vs › | $9.93B | 30.06x | 26.26x | 37.03x | 50.43x |
| Insulet Corp. (PODD)vs › | $9.33B | 32.67x | 40.51x | 73.82x | 73.82x |
| The Ensign Group, Inc. (ENSG)vs › | $10.03B | 28.67x | 36.84x | 40.02x | 35.83x |
| Bruker Corporation (BRKR)vs › | $9.21B | 116.51x | 164.71x | 91.71x | 80.37x |
| Align Technology, Inc. (ALGN)vs › | $10.13B | N/A | 31.78x | 40.89x | 51.25x |
| ImmunityBio, Inc. (IBRX)vs › | $10.15B | N/A | N/A | N/A | N/A |
EV/FCF
N/A
P/FCF
N/A
FCF Yield
N/A
Formula: EV/FCF = Enterprise Value / Free Cash Flow
EV/FCF vs P/FCF:
EV/FCF = Enterprise Value / Free Cash Flow (TTM)
Enterprise value to free cash flow compares total company value to the cash the business generates after capital expenditures.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
